| Outcome Measures: |
Primary: Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events, The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded., Baseline through End of Study (up to 7.5 years)|Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause, All deaths identified during the original record study and discovered after the re-adjudication efforts began were included., Baseline through End of Study (up to 7.5 years)|Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions, IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin., Baseline through End of Study (up to 7.5 years)|Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions, Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury., Baseline through End of Study (up to 7.5 years)|Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions, The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as "unknown deaths," but were counted as CV deaths for the analysis of this endpoint., Baseline through End of Study (up to 7.5 years)|Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions, The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths., Baseline through End of Study (up to 7.5 years)|Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions, The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme \>= 2x the ULN or CK \> 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI., Baseline through End of Study (up to 7.5 years)|Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions, The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia., Baseline through End of Study (up to 7.5 years)|Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions, Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke., Baseline through End of Study (up to 7.5 years)|Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions, The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury., Baseline through End of Study (up to 7.5 years) | Secondary: Number of Participants With Cardiovascular Events and All-cause Deaths, Composites of participants with first cardiovascular (CV) hospitalisations and CV death or all-cause death and individual first events of acute myocardial infarction (MI) , stroke, congestive heart failure (CHF), CV death, and all-cause death., Baseline through End of Study (up to 7.5 years)|Total Number of Cardiovascular Hospitalisations and Cardiovascular Deaths, The total number of events for individual components of cardiovascular (CV) hospitalisations and cardiovascular deaths were recorded. MI, myocardial infarction., Baseline through End of Study (up to 7.5 years)|Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum, Participants with first cardiovascular death (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) were recorded by study stratum., Baseline through End of Study (up to 7.5 years)|Number of Participants With CV/Microvascular Events, The number of participants with first cardiovascular or microvascular events (renal, foot, eye) were recorded., Baseline through End of Study (up to 7.5 years)|Number of Participants With Glycaemic Failure Events, Failure of glycaemic control was defined as two consecutive HbA1c values of ≥8.5 percent, or HbA1c ≥8.5percent at a single visit, after which the subject was either moved to the post-randomised treatment phase or triple therapy was started., Baseline through to end of randomised dual therapy|Number of Participants With Addition of Third Oral Agent/Switch to Insulin, The number of participants with addition of a third oral agent or switch to insulin from randomised dual combination treatment were recorded., Baseline through End of Study (up to 7.5 years)|The Number of Participants Starting Insulin at Any Time During the Study, The number of participants starting insulin at any time during the study was recorded., Baseline through End of Study (up to 7.5 years)|Model Adjusted Change From Baseline in HbA1c at Month 60, Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in HbA1c was calculated as the value at Month 60 minus the Baseline value., Baseline and Month 60 of randomised dual therapy treatment period|Model Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60, Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in fasting plasma glucose was calculated as the value at Month 60 minus the Baseline value., Baseline to Month 60 of the randomised dual therapy treatment period|Model Adjusted Mean Change From Baseline in Insulin and Pro-insulin at Month 60, Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in insulin and pro-insulin was calculated as the value at Month 60 minus the Baseline value., Baseline to Month 60 of the randomised dual therapy treatment period|Number of HbA1c and Fasting Plasma Glucose (FPG) Responders at Month 60, Number of responders, i.e., participants meeting glycaemic targets (HbA1c less than or equal to 7 percent, FPG less than or equal to 7 mmol/L), Baseline to Month 60 of the randomised dual therapy treatment period|Model Adjusted Ratio to Baseline (Expressed as a Percentage) Homeostasis Model Assessment (HOMA) Beta Cell Function and Insulin Sensitivity at Month 60, The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in HOMA beta-cell function and insulin sensitivity was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\])., Baseline to Month 60 of the randomised dual therapy treatment phase|Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC), Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Triglycerides, and Free Fatty Acids (FFAs) at Month 60, The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in TC, LDL cholesterol, HDL cholesterol, triglycerides, and FFAs was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\])., Baseline to Month 60 of the randomised dual therapy treatment phase|Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC):High-density Lipoprotein (HDL) Cholesterol and Low-density Lipoprotein (LDL) Cholesterol:HDL Cholesterol Ratios at Month 60, The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in TC:HDL cholesterol and LDL cholesterol:HDL cholesterol was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\])., Baseline to Month 60 of the randomised dual therapy treatment period|Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60, The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in Apo-B was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\])., Baseline to Month 60 of the randomised dual therapy treatment period|Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 60, The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in urinary albumin creatinine ratio was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\])., Baseline to Month 60 of the randomised dual therapy treatment phase|Model Adjusted Change From Baseline in Body Weight at Month 60, Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in body weight was calculated as the value at Month 60 minus the Baseline value., Baseline to Month 60 of the randomised dual therapy treatment phase|Model Adjusted Change From Baseline in Alanine Aminotransferase at Month 60, Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in alanine aminotransferase was calculated as the value at Month 60 minus the Baseline value., Baseline to Month 60 of the randomised dual therapy treatment phase|Model Adjusted Change From Baseline in Waist Circumference at Month 60, Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in waist circumference was calculated as the value at Month 60 minus the Baseline value., Baseline to Month 60 of the randomised dual therapy treatment phase|Model Adjusted Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 60, Model adjusted (adjusted for any imbalances in the baseline values between within treatment groups) change from baseline in SBP and DBP was calculated as the value at Month 60 minus the Baseline value., Baseline to Month 60 of the randomised dual therapy treatment phase|Model Adjusted Ratio to Baseline (Expressed as a Percentage) for C-Reactive Protein at Month 60, The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in C-Reactive Protein was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\])., Baseline to Month 60 of the randomised dual therapy treatment phase|Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Fibrinogen at Month 60, The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in fibrinogen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\])., Baseline to Month 60 of the randomised dual therapy treatment phase|Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Plasminogen Activator Inhibitor-1 (PAI-1) Antigen at Month 60, The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in plasminogen activator inhibitor-1 (PAI-1) antigen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\])., Baseline to Month 60 of the randomised dual therapy treatment phase|Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Main Study + Observational Follow-up Combined, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE., From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Observational Follow-up, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE., From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)|Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Main Study + Observational Follow-up Combined, The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE., From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Observational Follow-up, The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE., From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)|Number of Participants Who Died Due to the Indicated Cancer-related Event: Main Study + Observational Follow-up Combined, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE., From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Participants Who Died Due to the Indicated Cancer-related Event: Observational Follow-up, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE., From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)|Number of Participants With a Bone Fracture Event - Overall and by Gender: Main Study and Observational Follow-up Combined, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant., From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Participants With a Bone Fracture Event - Overall and by Gender: Observational Follow-up, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant., From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)|Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Main Study + Observational Follow-up Combined, The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE., From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Observational Follow-up, The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE., From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)|Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant., From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Participants With the Indicated Bone Fracture by Fracture Site: Main Study + Observational Follow-up Combined, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant., From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Participants With the Indicated Bone Fracture by Fracture Site: Observational Follow-up, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant., From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)|Number of Participants With Potentially High Morbidity Fractures: Main Study + Observational Follow-up Combined, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown)., From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Participants With Potentially High Morbidity Fracture Events and Non-high Morbidity Fracture Events, in Participants With Prior Hand/Upper Arm/Foot Fractures (H/UA/FF): Main Study + Observational Follow-up Combined, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown)., From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Participants With Bone Fracture Events of the Indicated Cause: Main Study + Observational Follow-up Combined, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant., From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Participants With Bone Fracture Events of the Indicated Cause: Observational Follow-up, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable.", From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)|Number of Bone Fracture Events With the Indicated Outcome: Main Study + Observational Follow-up Combined, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable.", From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)|Number of Bone Fracture Events With the Indicated Outcome: Observational Follow-up, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable.", From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)|Number of Participants With the Indicated Serious Adverse Event: Observational Follow-up, The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE., From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
|
| Locations: |
GSK Investigational Site, Miranda, New South Wales, 2228, Australia|GSK Investigational Site, Randwick, New South Wales, 2031, Australia|GSK Investigational Site, Wollongong, New South Wales, 2500, Australia|GSK Investigational Site, Carina Heights, Queensland, 4152, Australia|GSK Investigational Site, Kippa Ring, Queensland, 4021, Australia|GSK Investigational Site, Sherwood, Queensland, 4075, Australia|GSK Investigational Site, Keswick, South Australia, 5035, Australia|GSK Investigational Site, North Adelaide, South Australia, 5006, Australia|GSK Investigational Site, Port Lincoln, South Australia, 5606, Australia|GSK Investigational Site, Heidelberg, Victoria, 3084, Australia|GSK Investigational Site, Malvern, Victoria, 3144, Australia|GSK Investigational Site, Antwerpen, 2000, Belgium|GSK Investigational Site, Arlon, 6700, Belgium|GSK Investigational Site, Brussels, 1090, Belgium|GSK Investigational Site, Edegem, 2650, Belgium|GSK Investigational Site, Genk, 3600, Belgium|GSK Investigational Site, Gent, 9000, Belgium|GSK Investigational Site, Kortrijk, 8500, Belgium|GSK Investigational Site, Liège, 4000, Belgium|GSK Investigational Site, Moerkerke, 8340, Belgium|GSK Investigational Site, Oostham, 3945, Belgium|GSK Investigational Site, Roeselare, 8800, Belgium|GSK Investigational Site, Sint Gillis-Waas, 9170, Belgium|GSK Investigational Site, Vilvoorde, 1800, Belgium|GSK Investigational Site, Pleven, 5800, Bulgaria|GSK Investigational Site, Plovdiv, 4002, Bulgaria|GSK Investigational Site, Sofia, 1233, Bulgaria|GSK Investigational Site, Sofia, 1301, Bulgaria|GSK Investigational Site, Sofia, 1303, Bulgaria|GSK Investigational Site, Sofia, 1431/1000, Bulgaria|GSK Investigational Site, Sofia, 1606, Bulgaria|GSK Investigational Site, Varna, 9010, Bulgaria|GSK Investigational Site, Krapinske Toplice, 49217, Croatia|GSK Investigational Site, Rijeka, 51000, Croatia|GSK Investigational Site, Slavonski Brod, 35000, Croatia|GSK Investigational Site, Varaždin, 42000, Croatia|GSK Investigational Site, Zagreb, 10000, Croatia|GSK Investigational Site, Brno, 625 00, Czech Republic|GSK Investigational Site, Ceske Budejovice, 370 87, Czech Republic|GSK Investigational Site, Holice V Cechach, 534 01, Czech Republic|GSK Investigational Site, Hradec Kralove, 500 05, Czech Republic|GSK Investigational Site, Jindrichuv Hradec, 377 38, Czech Republic|GSK Investigational Site, Ostrava Poruba, 708 52, Czech Republic|GSK Investigational Site, Pisek, 397 01, Czech Republic|GSK Investigational Site, Praha 2, 128 42, Czech Republic|GSK Investigational Site, Praha 4, 140 21, Czech Republic|GSK Investigational Site, Rakovnik, 269 01, Czech Republic|GSK Investigational Site, Tabor, 390 00, Czech Republic|GSK Investigational Site, Trutnov, 541 21, Czech Republic|GSK Investigational Site, Aalborg, DK-9100, Denmark|GSK Investigational Site, Aarhus, Denmark|GSK Investigational Site, Copenhagen, 2300, Denmark|GSK Investigational Site, Glostrup, Denmark|GSK Investigational Site, Hilleroed, 3400, Denmark|GSK Investigational Site, Koge, 4600, Denmark|GSK Investigational Site, Kolding, DK-6000, Denmark|GSK Investigational Site, København NV, Denmark|GSK Investigational Site, Naestved, 4700, Denmark|GSK Investigational Site, Odense C, DK-5000, Denmark|GSK Investigational Site, Silkeborg, 8600, Denmark|GSK Investigational Site, Slagelse, 4200, Denmark|GSK Investigational Site, Paide, 72714, Estonia|GSK Investigational Site, Parnu, 80018, Estonia|GSK Investigational Site, Rakvere, 44316, Estonia|GSK Investigational Site, Saku, 75501, Estonia|GSK Investigational Site, Tallinn, 10138, Estonia|GSK Investigational Site, Tallinn, 1162, Estonia|GSK Investigational Site, Tallinn, 11911, Estonia|GSK Investigational Site, Tallinn, 13415, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Viljandi, 71024, Estonia|GSK Investigational Site, Espoo, 02600, Finland|GSK Investigational Site, Espoo, 02710, Finland|GSK Investigational Site, Hanko, 10900, Finland|GSK Investigational Site, Helsinki, 00150, Finland|GSK Investigational Site, Helsinki, 00810, Finland|GSK Investigational Site, Helsinki, 00930, Finland|GSK Investigational Site, Hyvinkaa, 05800, Finland|GSK Investigational Site, Jyväskylä, 40100, Finland|GSK Investigational Site, Kerava, 04200, Finland|GSK Investigational Site, Kuopio, 70210, Finland|GSK Investigational Site, Lahti, 15850, Finland|GSK Investigational Site, Lappeenranta, 53100, Finland|GSK Investigational Site, Oulun kaupunki, 90015, Finland|GSK Investigational Site, Riihimäki, 11130, Finland|GSK Investigational Site, Rovaniemi, Finland|GSK Investigational Site, Seinajoki, 60220, Finland|GSK Investigational Site, Tampere, 33100, Finland|GSK Investigational Site, Turku, 20100, Finland|GSK Investigational Site, Turku, 20700, Finland|GSK Investigational Site, Bully Les Mines, Nord-Pas-de-Calais, 62160, France|GSK Investigational Site, Amilly, 28300, France|GSK Investigational Site, Arras, 62000, France|GSK Investigational Site, Aspach le Bas 68700, 68700, France|GSK Investigational Site, Aubagne, 13400, France|GSK Investigational Site, Auchy les Hesdin, 62770, France|GSK Investigational Site, Azille, 11700, France|GSK Investigational Site, Beaumont Le Roger, 21170, France|GSK Investigational Site, Beaumont sur Leze, 31870, France|GSK Investigational Site, Belfort, 90000, France|GSK Investigational Site, Belpech, 11420, France|GSK Investigational Site, Blotzheim, France|GSK Investigational Site, Bondy, 93143, France|GSK Investigational Site, BP 1542 Dijon, 21034, France|GSK Investigational Site, Broglie, 27270, France|GSK Investigational Site, Calmont, 31560, France|GSK Investigational Site, Carbonne, 31390, France|GSK Investigational Site, Carcassonne 11000, 11000, France|GSK Investigational Site, Carcassonne, 11000, France|GSK Investigational Site, Carcassonne, France|GSK Investigational Site, Cassis, 13260, France|GSK Investigational Site, Castelnaudary, 11400, France|GSK Investigational Site, Catelnaudary, 11400, France|GSK Investigational Site, Cernay, 68700, France|GSK Investigational Site, Champhol, 28300, France|GSK Investigational Site, Chartres, 28000, France|GSK Investigational Site, Colmar, 68000, France|GSK Investigational Site, Corbeil Essonne, 91014, France|GSK Investigational Site, Coursan, 11110, France|GSK Investigational Site, Cuincy, 59553, France|GSK Investigational Site, Danjoutin, 90400, France|GSK Investigational Site, Dessenheim, 68600, France|GSK Investigational Site, Dieppe, 76200, France|GSK Investigational Site, Dunkerque, 59385, France|GSK Investigational Site, Epernon, 28230, France|GSK Investigational Site, Gemenos, 13420, France|GSK Investigational Site, Hanches, 28130, France|GSK Investigational Site, Hautot sur Mer, 76550, France|GSK Investigational Site, Husseren Wesserling, 68470, France|GSK Investigational Site, Kembs, 68680, France|GSK Investigational Site, La Barre En Ouche, 27330, France|GSK Investigational Site, La Verdière, 83560, France|GSK Investigational Site, Labarth-Sur-Leze, 31860, France|GSK Investigational Site, Labarthe-Sur-Leze, 31860, France|GSK Investigational Site, Le Grau Du Roi, 30240, France|GSK Investigational Site, Le Lherm 31600, 31600, France|GSK Investigational Site, Le Perray En Yvelines, 78610, France|GSK Investigational Site, Lezignan-Corbières, 11200, France|GSK Investigational Site, Maintenon, 28130, France|GSK Investigational Site, Marseille, 13001, France|GSK Investigational Site, Marseille, 13003, France|GSK Investigational Site, Marseille, 13008, France|GSK Investigational Site, Marseille, 13011, France|GSK Investigational Site, Marseille, 13013, France|GSK Investigational Site, Marseille, 13014, France|GSK Investigational Site, Marseille, 13016, France|GSK Investigational Site, Masevaux, 68290, France|GSK Investigational Site, Maubeuge, 59600, France|GSK Investigational Site, Monfort sur Risle, 27290, France|GSK Investigational Site, Mulhouse, 68100, France|GSK Investigational Site, Muret, 31600, France|GSK Investigational Site, Nassandres, 27550, France|GSK Investigational Site, Nevers cedex, 58033, France|GSK Investigational Site, Nogent le Phaye, 28630, France|GSK Investigational Site, Orbec, 14290, France|GSK Investigational Site, Paris, 75730, France|GSK Investigational Site, Pierre Benite Cedex, 69495, France|GSK Investigational Site, Pierres, 28130, France|GSK Investigational Site, Pinsaguel, 31120, France|GSK Investigational Site, Roux Mesnil Bouteille, 76370, France|GSK Investigational Site, Rugles, 27250, France|GSK Investigational Site, Saint Leger sur Yvelines, 78610, France|GSK Investigational Site, Saint-Eulalie Badens, 11800, France|GSK Investigational Site, Seysses, 31600, France|GSK Investigational Site, Thann, 68800, France|GSK Investigational Site, Thiberville, 27230, France|GSK Investigational Site, Toulouse, 31000, France|GSK Investigational Site, Toulouse, 31400, France|GSK Investigational Site, Toulouse, 31500, France|GSK Investigational Site, Trebbes, 01800, France|GSK Investigational Site, Trebes, 11800, France|GSK Investigational Site, Valenciennes, 59322, France|GSK Investigational Site, Vogelsheim, 68600, France|GSK Investigational Site, Voves, 28150, France|GSK Investigational Site, Wittenheim, 68270, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, 69120, Germany|GSK Investigational Site, Sinsheim, Baden-Wuerttemberg, 74889, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, 70197, Germany|GSK Investigational Site, Kronach, Bayern, 96317, Germany|GSK Investigational Site, Wuerzburg, Bayern, 97070, Germany|GSK Investigational Site, Kronberg, Hessen, 61476, Germany|GSK Investigational Site, Ober-Moerlen, Hessen, 61239, Germany|GSK Investigational Site, Offenbach, Hessen, 63071, Germany|GSK Investigational Site, Wetzlar, Hessen, 35578, Germany|GSK Investigational Site, Bad Lauterberg, Niedersachsen, 37431, Germany|GSK Investigational Site, Beckum, Nordrhein-Westfalen, 59269, Germany|GSK Investigational Site, Menden, Nordrhein-Westfalen, 58706, Germany|GSK Investigational Site, Gau-Algesheim, Rheinland-Pfalz, 55435, Germany|GSK Investigational Site, Kallstadt, Rheinland-Pfalz, 67169, Germany|GSK Investigational Site, Lambrecht, Rheinland-Pfalz, 67466, Germany|GSK Investigational Site, Rhaunen, Rheinland-Pfalz, 55624, Germany|GSK Investigational Site, Speyer, Rheinland-Pfalz, 67346, Germany|GSK Investigational Site, Friedrichsthal, Saarland, 66299, Germany|GSK Investigational Site, Burgstaedt, Sachsen, 09217, Germany|GSK Investigational Site, Chemnitz, Sachsen, 09130, Germany|GSK Investigational Site, Dresden, Sachsen, 01307, Germany|GSK Investigational Site, Leipzig, Sachsen, 04103, Germany|GSK Investigational Site, Suhl, Thueringen, 98529, Germany|GSK Investigational Site, Hamburg, 20249, Germany|GSK Investigational Site, Athens, 115 27, Greece|GSK Investigational Site, Athens, 11521, Greece|GSK Investigational Site, Athens, 11527, Greece|GSK Investigational Site, Athens, 18537, Greece|GSK Investigational Site, Haidari, Athens, 12462, Greece|GSK Investigational Site, Ioannina, 45001, Greece|GSK Investigational Site, Maroussi, 15123, Greece|GSK Investigational Site, Patra, 26335, Greece|GSK Investigational Site, Patra, 26500, Greece|GSK Investigational Site, Piraeus-Athens, 18454, Greece|GSK Investigational Site, Piraeus-Athens, 18536, Greece|GSK Investigational Site, Thessalonikis, 57010, Greece|GSK Investigational Site, Thessaloniki, 564 29, Greece|GSK Investigational Site, Budapest, 1062, Hungary|GSK Investigational Site, Budapest, 1083, Hungary|GSK Investigational Site, Budapest, 1096, Hungary|GSK Investigational Site, Budapest, 1097, Hungary|GSK Investigational Site, Budapest, 1115, Hungary|GSK Investigational Site, Budapest, 1125, Hungary|GSK Investigational Site, Budapest, 1145, Hungary|GSK Investigational Site, Debrecen, 4043, Hungary|GSK Investigational Site, Eger, Hungary|GSK Investigational Site, Gyor, 9024, Hungary|GSK Investigational Site, Gyula, 5701, Hungary|GSK Investigational Site, Kurtag99, Hungary|GSK Investigational Site, Nyiregyháza, 4400, Hungary|GSK Investigational Site, Patkaj98, Hungary|GSK Investigational Site, Siofok, 8601, Hungary|GSK Investigational Site, Szentes, 6600, Hungary|GSK Investigational Site, Szombathely, 9700, Hungary|GSK Investigational Site, Veszprem, 8200, Hungary|GSK Investigational Site, Zalaegerszeg, 8900, Hungary|GSK Investigational Site, Reggio Calabria, Calabria, 89100, Italy|GSK Investigational Site, Napoli, Campania, 80136, Italy|GSK Investigational Site, Nocera Inferiore (SA), Campania, 84014, Italy|GSK Investigational Site, Salerno, Campania, 84100, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, 40138, Italy|GSK Investigational Site, Rimini, Emilia-Romagna, 47900, Italy|GSK Investigational Site, Roma, Lazio, 00155, Italy|GSK Investigational Site, Roma, Lazio, 00168, Italy|GSK Investigational Site, Genova, Liguria, 16132, Italy|GSK Investigational Site, Brescia, Lombardia, 25123, Italy|GSK Investigational Site, Milano, Lombardia, 20162, Italy|GSK Investigational Site, San Donato (MI), Lombardia, 20097, Italy|GSK Investigational Site, Treviglio (BG), Lombardia, 13115, Italy|GSK Investigational Site, Campobasso, Molise, 86100, Italy|GSK Investigational Site, Torino, Piemonte, 10122, Italy|GSK Investigational Site, Cagliari, Sardegna, 09127, Italy|GSK Investigational Site, Sassari, Sardegna, 07100, Italy|GSK Investigational Site, Palermo, Sicilia, 90127, Italy|GSK Investigational Site, Pisa, Toscana, 56126, Italy|GSK Investigational Site, Bari, 70124, Italy|GSK Investigational Site, Parma, 43100, Italy|GSK Investigational Site, Roma, 00168, Italy|GSK Investigational Site, Jekabpils, LV 5201, Latvia|GSK Investigational Site, Lagzdi60, Latvia|GSK Investigational Site, Limbazi, LV 4001, Latvia|GSK Investigational Site, Ogre, LV 5001, Latvia|GSK Investigational Site, Riga, 1006, Latvia|GSK Investigational Site, Riga, LV 1011, Latvia|GSK Investigational Site, Riga, LV 1057, Latvia|GSK Investigational Site, Riga, LV1002, Latvia|GSK Investigational Site, Sturii59, Latvia|GSK Investigational Site, Tukums, LV 3100, Latvia|GSK Investigational Site, Kaunas, LT-47144, Lithuania|GSK Investigational Site, Kaunas, LT-49476, Lithuania|GSK Investigational Site, Kaunas, LT-50009, Lithuania|GSK Investigational Site, Kaunas, LT-51270, Lithuania|GSK Investigational Site, Klaipeda, 92304, Lithuania|GSK Investigational Site, Vilnius, LT 08661, Lithuania|GSK Investigational Site, Vilnius, LT-04318, Lithuania|GSK Investigational Site, Vilnius, LT-10103, Lithuania|GSK Investigational Site, Geleen, 6160 BB, Netherlands|GSK Investigational Site, Groningen, 9711 SG, Netherlands|GSK Investigational Site, Hengelo, 7555 DL, Netherlands|GSK Investigational Site, Hoogvliet, 3192 JN, Netherlands|GSK Investigational Site, Kerkrade, 6461 XP, Netherlands|GSK Investigational Site, Landgraaf, 6373 JS, Netherlands|GSK Investigational Site, Musselkanaal, 9581 AD, Netherlands|GSK Investigational Site, Nijmegen, 6525 EC, Netherlands|GSK Investigational Site, Oude Pekela, 9665 AR, Netherlands|GSK Investigational Site, Ridderkerk, 2985 BV, Netherlands|GSK Investigational Site, Rijswijk, 2281 AK, Netherlands|GSK Investigational Site, Roosendaal, 4701 LJ, Netherlands|GSK Investigational Site, Rotterdam, 3021 HC, Netherlands|GSK Investigational Site, Rotterdam, 3082 KC, Netherlands|GSK Investigational Site, St. Willebrord, 4711 EG, Netherlands|GSK Investigational Site, Zoetermeer, 2724 EK, Netherlands|GSK Investigational Site, Zwijndrecht, 3331 AE, Netherlands|GSK Investigational Site, Zwijndrecht, 3334 XA, Netherlands|GSK Investigational Site, Christchurch, 8011, New Zealand|GSK Investigational Site, Dunedin, 9016, New Zealand|GSK Investigational Site, Hastings, Private Bag 9014, New Zealand|GSK Investigational Site, Otahuhu, Auckland, 2025, New Zealand|GSK Investigational Site, Palmerston North, 4410, New Zealand|GSK Investigational Site, Takapuna, Auckland, 0620, New Zealand|GSK Investigational Site, Tauranga, 3112, New Zealand|GSK Investigational Site, Wellington, 6002, New Zealand|GSK Investigational Site, Bialystok, 15-276, Poland|GSK Investigational Site, Bydgoszcz, 85 822, Poland|GSK Investigational Site, Gdansk, 80 211, Poland|GSK Investigational Site, Grudziadz, 86-300, Poland|GSK Investigational Site, Krakow, 31 261, Poland|GSK Investigational Site, Krakow, 31 501, Poland|GSK Investigational Site, Lodz, 90 030, Poland|GSK Investigational Site, Lublin, 02 081, Poland|GSK Investigational Site, Lublin, 20-718, Poland|GSK Investigational Site, Olsztyn, 10 461, Poland|GSK Investigational Site, Poznan, 60-834, Poland|GSK Investigational Site, Poznan, 61 696, Poland|GSK Investigational Site, Warszawa, 01 887, Poland|GSK Investigational Site, Warszawa, 01-337, Poland|GSK Investigational Site, Warszawa, 02 507, Poland|GSK Investigational Site, Warszawa, 02-042, Poland|GSK Investigational Site, Wroclaw, 50-127, Poland|GSK Investigational Site, Bucharest, 020475, Romania|GSK Investigational Site, Bucuresti, 011234, Romania|GSK Investigational Site, Bucuresti, 022448, Romania|GSK Investigational Site, Cluj-Napoca, 400006, Romania|GSK Investigational Site, Craiova, 2000642, Romania|GSK Investigational Site, Iasi, 700111, Romania|GSK Investigational Site, Timisoara, 293406, Romania|GSK Investigational Site, Moscow, 115 280, Russian Federation|GSK Investigational Site, Moscow, 117049, Russian Federation|GSK Investigational Site, Moscow, 125367, Russian Federation|GSK Investigational Site, Moscow, 129110, Russian Federation|GSK Investigational Site, St Petersburg, 195257, Russian Federation|GSK Investigational Site, St-Petersburg, 194291, Russian Federation|GSK Investigational Site, Banska Bystrica, 975 17, Slovakia|GSK Investigational Site, Bratislava, 811 08, Slovakia|GSK Investigational Site, Bratislava, 813 69, Slovakia|GSK Investigational Site, Bratislava, 82102, Slovakia|GSK Investigational Site, Bratislava, 82108, Slovakia|GSK Investigational Site, Kosice, 040 11, Slovakia|GSK Investigational Site, Kosice, 041 90, Slovakia|GSK Investigational Site, Kysucke Nove Mesto, 024 01, Slovakia|GSK Investigational Site, Lubochna, 034 91, Slovakia|GSK Investigational Site, Lucenec, 984 01, Slovakia|GSK Investigational Site, Presov, 08001, Slovakia|GSK Investigational Site, Prievidza, 97201, Slovakia|GSK Investigational Site, Sahy, 936 01, Slovakia|GSK Investigational Site, Samorin, 931 01, Slovakia|GSK Investigational Site, Trencin, 911 01, Slovakia|GSK Investigational Site, Zilina, 010 01, Slovakia|GSK Investigational Site, Badalona, 08911, Spain|GSK Investigational Site, Barcelona, 08025, Spain|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, Benidorm, 03500, Spain|GSK Investigational Site, Bilbao, 48903, Spain|GSK Investigational Site, Caceres, 10003, Spain|GSK Investigational Site, Cadiz, 11009, Spain|GSK Investigational Site, Granada, 18012, Spain|GSK Investigational Site, Madrid, 28034, Spain|GSK Investigational Site, Madrid, 28040, Spain|GSK Investigational Site, Palma de Mallorca, 7014, Spain|GSK Investigational Site, Reus, 43201, Spain|GSK Investigational Site, Santander, 38008, Spain|GSK Investigational Site, Vazquc56, Spain|GSK Investigational Site, Vizcaya, 48910, Spain|GSK Investigational Site, Vizcaya, 48920, Spain|GSK Investigational Site, Eksjö, SE-575 81, Sweden|GSK Investigational Site, Göteborg, SE-413 45, Sweden|GSK Investigational Site, Göteborg, SE-416 65, Sweden|GSK Investigational Site, Göteborg, SE-417 17, Sweden|GSK Investigational Site, Helsingborg, SE-254 37, Sweden|GSK Investigational Site, Kristianstad, SE-291 85, Sweden|GSK Investigational Site, Kungälv, SE-442 83, Sweden|GSK Investigational Site, Köping, SE-73181, Sweden|GSK Investigational Site, Linköpiing, SE-582 25, Sweden|GSK Investigational Site, Linköping, SE-582 46, Sweden|GSK Investigational Site, Lund, SE-221 85, Sweden|GSK Investigational Site, Mora, SE-792 85, Sweden|GSK Investigational Site, Nacka, SE-131 83, Sweden|GSK Investigational Site, Norrköping, SE-602 20, Sweden|GSK Investigational Site, Oskarshamn, SE-572 28, Sweden|GSK Investigational Site, Skene, SE-511 62, Sweden|GSK Investigational Site, Stockholm, SE-182 88, Sweden|GSK Investigational Site, Uddevalla, SE-451 40, Sweden|GSK Investigational Site, Umeå, SE-901 85, Sweden|GSK Investigational Site, Uppsala, SE-751 25, Sweden|GSK Investigational Site, Vadstena, SE-592 32, Sweden|GSK Investigational Site, Dnepropetrovsk, 49044, Ukraine|GSK Investigational Site, Kharkiv, 61002, Ukraine|GSK Investigational Site, Kiev, 02175, Ukraine|GSK Investigational Site, Kiev, 04114, Ukraine|GSK Investigational Site, Kyiv, 01004, Ukraine|GSK Investigational Site, Lvov, 79010, Ukraine|GSK Investigational Site, Vinnitsa, 21010, Ukraine|GSK Investigational Site, Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom|GSK Investigational Site, Fowley, Cornwall, PL23 1DT, United Kingdom|GSK Investigational Site, Chesterfield, Derbyshire, S40 4TF, United Kingdom|GSK Investigational Site, Chesterfield, Derbyshire, S44 6DE, United Kingdom|GSK Investigational Site, Airdrie, Lanarkshire, ML6 0JS, United Kingdom|GSK Investigational Site, Glasgow, Lanarkshire, G51 4TF, United Kingdom|GSK Investigational Site, Glasgow, Lanarkshire, United Kingdom|GSK Investigational Site, Hamilton, Lanarkshire, ML3 0DR, United Kingdom|GSK Investigational Site, Motherwell, Lanarkshire, ML1 3JX, United Kingdom|GSK Investigational Site, Leicester, Leicestershire, LE1 5WW, United Kingdom|GSK Investigational Site, Northampton, Northamptonshire, NN1 5BD, United Kingdom|GSK Investigational Site, Northampton, Northamptonshire, NN5 7AQ, United Kingdom|GSK Investigational Site, Linwood, Renfrewshire, United Kingdom|GSK Investigational Site, Paisley, Renfrewshire, PA1 1UB, United Kingdom|GSK Investigational Site, Frome, Somerset, BA11 1EZ, United Kingdom|GSK Investigational Site, Glastonbury, Somerset, BA6 9LP, United Kingdom|GSK Investigational Site, Rugby, Warwickshire, CV21 3SP, United Kingdom|GSK Investigational Site, Rugby, Warwickshire, CV22 5PX, United Kingdom|GSK Investigational Site, Corsham, Wiltshire, SN13 9DL, United Kingdom|GSK Investigational Site, Trowbridge, Wiltshire, BA14 8QA, United Kingdom|GSK Investigational Site, Trowbridge, Wiltshire, BA14 9AR, United Kingdom|GSK Investigational Site, Westbury, Wiltshire, BA13 3JD, United Kingdom|GSK Investigational Site, Airdrie, ML6 0JH, United Kingdom|GSK Investigational Site, Airdrie, ML6 0JU, United Kingdom|GSK Investigational Site, Ashford, TW15 2TU, United Kingdom|GSK Investigational Site, Bath, BA2 3HT, United Kingdom|GSK Investigational Site, Chesterfield, S40 1LE, United Kingdom|GSK Investigational Site, Chippenham, SN15 2SB, United Kingdom|GSK Investigational Site, Coatbridge, ML5 3AP, United Kingdom|GSK Investigational Site, Colney, NR4 7UY, United Kingdom|GSK Investigational Site, Cumbernauld, G67 3BE, United Kingdom|GSK Investigational Site, Dronfield, S18 1RU, United Kingdom|GSK Investigational Site, Dumbarton, G82 1PW, United Kingdom|GSK Investigational Site, East Kilbride, G75 8RG, United Kingdom|GSK Investigational Site, Falmouth, TR11 2LH, United Kingdom|GSK Investigational Site, Garston, Watford, WD2 6EB, United Kingdom|GSK Investigational Site, Gateshead, NE9 6SX, United Kingdom|GSK Investigational Site, Glasgow, G5 OPQ, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Hamilton, ML3 8AA, United Kingdom|GSK Investigational Site, Harrow, HA3 7LT, United Kingdom|GSK Investigational Site, Kirkintilloch, G66 1JB, United Kingdom|GSK Investigational Site, Leigh on Sea, SS9 2SQ, United Kingdom|GSK Investigational Site, Motherwell, ML1 2PS, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, NE1 4LP, United Kingdom|GSK Investigational Site, Newport, PO30 5TG, United Kingdom|GSK Investigational Site, Nottingham, NG5 1PB, United Kingdom|GSK Investigational Site, Old Whittington, Chesterfield, S41 9JZ, United Kingdom|GSK Investigational Site, Paisley, PA3 2DY, United Kingdom|GSK Investigational Site, Penzance, TR18 4JH, United Kingdom|GSK Investigational Site, Rubery, Birmingham, B45 9JT, United Kingdom|GSK Investigational Site, Sheffield, S5 7QB, United Kingdom|GSK Investigational Site, Sheffield, S5 7TW, United Kingdom|GSK Investigational Site, Thornhill, Cardiff, CF14 9BB, United Kingdom|GSK Investigational Site, Thornhill, DG3 5AA, United Kingdom|GSK Investigational Site, Uddingston, G71 5SU, United Kingdom|GSK Investigational Site, Weston Super Mare, BS23 4BP, United Kingdom|GSK Investigational Site, Wishaw, ML2 7BQ, United Kingdom|GSK Investigational Site, Woking, GU21 1TD, United Kingdom|GSK Investigational Site, Worle, Weston-Super-Mare, BS22 6AJ, United Kingdom
|
